ALKS icon

Alkermes

30.28 USD
-0.18
0.59%
At close Jul 11, 4:00 PM EDT
After hours
30.28
+0.00
0.00%
1 day
-0.59%
5 days
5.21%
1 month
-2.95%
3 months
12.15%
6 months
6.81%
Year to date
5.32%
1 year
29.90%
5 years
59.12%
10 years
-53.45%
 

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 1,800

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

107% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 30

16% more capital invested

Capital invested by funds: $4.81B [Q4 2024] → $5.59B (+$779M) [Q1 2025]

8% more funds holding

Funds holding: 340 [Q4 2024] → 366 (+26) [Q1 2025]

0.74% more ownership

Funds ownership: 103.35% [Q4 2024] → 104.09% (+0.74%) [Q1 2025]

3% less repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 130

14% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]

46% less call options, than puts

Call options by funds: $7.68M | Put options by funds: $14.3M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$40
32%
upside
Avg. target
$42
39%
upside
High target
$45
49%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
UBS
Ashwani Verma
39%upside
$42
Buy
Upgraded
17 Jun 2025
Needham
Ami Fadia
49%upside
$45
Buy
Initiated
28 May 2025
RBC Capital
Leonid Timashev
32%upside
$40
Sector Perform
Maintained
2 May 2025
Baird
Joel Beatty
35%upside
$41
Outperform
Maintained
2 May 2025

Financial journalist opinion

Positive
Zacks Investment Research
1 week ago
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Positive
Zacks Investment Research
1 week ago
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
Neutral
PRNewsWire
1 month ago
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m.
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Neutral
PRNewsWire
1 month ago
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers.
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Negative
Zacks Investment Research
2 months ago
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
Positive
Seeking Alpha
2 months ago
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight gain with LYBALVI, addressing a major concern with mental health medications and supporting its market potential.
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
Neutral
Zacks Investment Research
2 months ago
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
Neutral
Seeking Alpha
2 months ago
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Uy Ear - Mizuho Securities Joel Beatty - Baird David Hoang - Deutsche Bank Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to Alkermes' First Quarter 2025 Financial Results Conference Call.
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
Neutral
PRNewsWire
2 months ago
Alkermes plc Reports First Quarter 2025 Financial Results
—    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year.
Alkermes plc Reports First Quarter 2025 Financial Results
Charts implemented using Lightweight Charts™